FAS and neoplasm: Since both Fas overexpression by itself, as well as different chemotherapeutic agents, can elicit Fas clustering in the absence of its ligand [43], it is highly likely that trabectedin triggers a FasL-independent activation of the death receptor in premature senescent tumor cells.